Summary Information:
Galera Therapeutics Inc. Common Stock
NASDAQ:GRTX


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Galera Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: GRTX
SEC CIK: 0001563577
Phone: 610-725-1500
2 WEST LIBERTY BLVD #100
MALVERN PA 19355

CEO:
Price when page updated: 0.1434 Date: 2023-11-30
Company Website:
galeratx.com

_Description: Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera's lead product candidate is avasopasem manganese (GC4419, also referred to as avasopasem), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC) has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera's second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA.

IPO YEAR:
2019
Sector:
Consumer Durables
Industry:
Specialty Chemicals
ADRTSO:

MarketCap:
7799837.00
Beta:
0.295195932853425
52 Week High:
12.99
52 Week Low:
1.19
52 Week Change:
-0.5649769585253457
Short Interest:

Short Date:

Shares Outstanding:
26438767
Dividend Rate:
0
Dividend Yield:
1.25%
ExDividend Date:

Latest EPS:

Latest EPS Date:
8 Sep 2022
Float:
0
return on Equity:
-
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
£70.300M
ttmEPS:
0
Revenue:
£569.800M
Gross Profit:

Cash:

Debt:

Institution Percent:
0.10%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
51.19%
Return on Assets:
-
Return on Capital:

Profit Margin:
-36.50%
Price to Sales:
3.64
Price To Book:
9.82
Short Ratio:
0.12
PE Ratio:
0
Employees:
38
1Y Guesstimate
N/A:N/A:N/A




__The following are links to various summary and news pages for
__Galera Therapeutics Inc. Common Stock [ GRTX ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-11-30